David Fox
Concepts (616)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 56 | 2026 | 1169 | 5.680 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 15 | 2025 | 100 | 3.230 |
Why?
| | Antigens, CD | 17 | 2025 | 555 | 2.990 |
Why?
| | CD13 Antigens | 7 | 2026 | 11 | 2.740 |
Why?
| | Synovial Membrane | 19 | 2026 | 124 | 2.510 |
Why?
| | Scleroderma, Systemic | 10 | 2026 | 123 | 2.230 |
Why?
| | Fibroblasts | 20 | 2026 | 1034 | 1.910 |
Why?
| | Th17 Cells | 8 | 2020 | 101 | 1.840 |
Why?
| | Interleukin-17 | 10 | 2015 | 118 | 1.810 |
Why?
| | T-Lymphocytes | 21 | 2024 | 1982 | 1.600 |
Why?
| | Gastrostomy | 4 | 2016 | 130 | 1.520 |
Why?
| | Scleroderma, Diffuse | 6 | 2022 | 10 | 1.400 |
Why?
| | Inflammation | 16 | 2026 | 2878 | 1.390 |
Why?
| | Arthritis, Experimental | 10 | 2026 | 141 | 1.360 |
Why?
| | Arthritis | 3 | 2026 | 96 | 1.310 |
Why?
| | Interleukin-4 | 4 | 2013 | 206 | 1.240 |
Why?
| | Rheumatology | 8 | 2019 | 133 | 1.200 |
Why?
| | T-Lymphocyte Subsets | 8 | 2020 | 415 | 1.110 |
Why?
| | Autoimmune Diseases | 9 | 2025 | 463 | 1.010 |
Why?
| | Cell Communication | 8 | 2017 | 324 | 0.940 |
Why?
| | Lymphocyte Activation | 10 | 2021 | 1126 | 0.910 |
Why?
| | Neoplasms | 6 | 2025 | 2875 | 0.900 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2026 | 72 | 0.900 |
Why?
| | Fundoplication | 2 | 2016 | 54 | 0.860 |
Why?
| | Antirheumatic Agents | 9 | 2026 | 304 | 0.860 |
Why?
| | Autoantigens | 6 | 2020 | 429 | 0.830 |
Why?
| | Cytokines | 14 | 2026 | 2061 | 0.820 |
Why?
| | Neutrophils | 7 | 2025 | 1134 | 0.810 |
Why?
| | Rheumatic Diseases | 7 | 2024 | 97 | 0.770 |
Why?
| | Tumor Necrosis Factor-alpha | 9 | 2026 | 1217 | 0.750 |
Why?
| | Humans | 125 | 2026 | 144759 | 0.740 |
Why?
| | Antifungal Agents | 4 | 2022 | 149 | 0.740 |
Why?
| | Gastroesophageal Reflux | 2 | 2016 | 236 | 0.730 |
Why?
| | Enteral Nutrition | 2 | 2014 | 216 | 0.710 |
Why?
| | Immunotherapy | 3 | 2025 | 653 | 0.710 |
Why?
| | Immune System Diseases | 2 | 2014 | 39 | 0.690 |
Why?
| | Psoriasis | 2 | 2023 | 112 | 0.680 |
Why?
| | Animals | 57 | 2026 | 38058 | 0.680 |
Why?
| | Silicones | 5 | 2017 | 29 | 0.640 |
Why?
| | B-Lymphocytes | 6 | 2025 | 876 | 0.600 |
Why?
| | Neovascularization, Physiologic | 4 | 2019 | 194 | 0.580 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2023 | 1129 | 0.570 |
Why?
| | Cells, Cultured | 20 | 2022 | 4154 | 0.560 |
Why?
| | Metacarpophalangeal Joint | 6 | 2014 | 22 | 0.530 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 467 | 0.530 |
Why?
| | Mice | 34 | 2024 | 18339 | 0.510 |
Why?
| | Anti-Inflammatory Agents | 2 | 2020 | 474 | 0.500 |
Why?
| | Skin | 8 | 2024 | 755 | 0.490 |
Why?
| | Extracellular Traps | 3 | 2025 | 57 | 0.490 |
Why?
| | Fibrosis | 5 | 2024 | 548 | 0.480 |
Why?
| | Interferon-gamma | 5 | 2019 | 784 | 0.480 |
Why?
| | Antigen-Presenting Cells | 7 | 2010 | 160 | 0.480 |
Why?
| | Hand Deformities, Acquired | 3 | 2013 | 4 | 0.480 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 66 | 0.480 |
Why?
| | Decision Making | 2 | 2014 | 975 | 0.470 |
Why?
| | Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2015 | 3 | 0.460 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 917 | 0.460 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 271 | 0.460 |
Why?
| | Dinoprost | 1 | 2015 | 49 | 0.460 |
Why?
| | Joint Prosthesis | 3 | 2017 | 22 | 0.450 |
Why?
| | Synoviocytes | 5 | 2022 | 18 | 0.440 |
Why?
| | Antibodies, Monoclonal | 10 | 2024 | 1519 | 0.440 |
Why?
| | Delivery of Health Care | 2 | 2012 | 947 | 0.430 |
Why?
| | Immunoconjugates | 3 | 2023 | 132 | 0.430 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2018 | 557 | 0.430 |
Why?
| | Cell Adhesion Molecules | 4 | 2024 | 178 | 0.420 |
Why?
| | Chemotaxis | 1 | 2015 | 122 | 0.420 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2014 | 6 | 0.410 |
Why?
| | Gastroscopy | 1 | 2014 | 18 | 0.410 |
Why?
| | Autoantibodies | 6 | 2023 | 1501 | 0.410 |
Why?
| | Periostitis | 1 | 2013 | 4 | 0.410 |
Why?
| | Intubation, Gastrointestinal | 1 | 2014 | 82 | 0.410 |
Why?
| | Professional-Family Relations | 2 | 2014 | 153 | 0.410 |
Why?
| | Societies, Medical | 2 | 2009 | 887 | 0.410 |
Why?
| | MAP Kinase Kinase Kinases | 3 | 2019 | 70 | 0.400 |
Why?
| | Fas Ligand Protein | 2 | 2013 | 60 | 0.400 |
Why?
| | Signal Transduction | 12 | 2026 | 5226 | 0.400 |
Why?
| | Arthralgia | 1 | 2013 | 61 | 0.390 |
Why?
| | Coculture Techniques | 6 | 2013 | 246 | 0.380 |
Why?
| | Cell Differentiation | 7 | 2019 | 2050 | 0.380 |
Why?
| | Hospital Medicine | 1 | 2014 | 92 | 0.380 |
Why?
| | Patient Navigation | 1 | 2014 | 104 | 0.370 |
Why?
| | Benzyl Compounds | 2 | 2024 | 2 | 0.370 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2194 | 0.370 |
Why?
| | Bone Resorption | 3 | 2020 | 80 | 0.370 |
Why?
| | Endothelial Cells | 7 | 2022 | 869 | 0.360 |
Why?
| | Dendritic Cells | 2 | 2007 | 499 | 0.360 |
Why?
| | Triazoles | 1 | 2013 | 184 | 0.360 |
Why?
| | Azetidines | 2 | 2024 | 45 | 0.360 |
Why?
| | Epitopes | 4 | 2013 | 485 | 0.360 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 2 | 2024 | 28 | 0.350 |
Why?
| | Growth Inhibitors | 1 | 2011 | 39 | 0.350 |
Why?
| | Male | 44 | 2026 | 72315 | 0.350 |
Why?
| | Anti-Citrullinated Protein Antibodies | 2 | 2026 | 126 | 0.350 |
Why?
| | Pyrimidines | 2 | 2022 | 532 | 0.340 |
Why?
| | Receptors, Interleukin-4 | 1 | 2011 | 16 | 0.340 |
Why?
| | Multiple Sclerosis | 3 | 2024 | 484 | 0.340 |
Why?
| | Cryptococcus neoformans | 2 | 2022 | 21 | 0.330 |
Why?
| | Female | 45 | 2026 | 78271 | 0.330 |
Why?
| | Molecular Targeted Therapy | 5 | 2018 | 432 | 0.330 |
Why?
| | CD40 Ligand | 2 | 2007 | 40 | 0.320 |
Why?
| | General Surgery | 2 | 2012 | 207 | 0.310 |
Why?
| | Teaching Rounds | 1 | 2011 | 73 | 0.310 |
Why?
| | CD5 Antigens | 1 | 2009 | 10 | 0.310 |
Why?
| | Tacrolimus | 2 | 2022 | 196 | 0.310 |
Why?
| | Ulna | 1 | 2009 | 35 | 0.300 |
Why?
| | Lymphocytes | 2 | 2024 | 382 | 0.290 |
Why?
| | B7-1 Antigen | 2 | 2010 | 55 | 0.290 |
Why?
| | Transcriptome | 2 | 2026 | 1045 | 0.290 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2019 | 15 | 0.290 |
Why?
| | Uveitis | 2 | 2022 | 148 | 0.290 |
Why?
| | Phosphodiesterase 4 Inhibitors | 2 | 2019 | 12 | 0.290 |
Why?
| | B-Lymphocyte Subsets | 1 | 2009 | 80 | 0.290 |
Why?
| | Ligands | 4 | 2025 | 673 | 0.280 |
Why?
| | Neovascularization, Pathologic | 3 | 2020 | 286 | 0.270 |
Why?
| | Inhibitor of Differentiation Protein 1 | 2 | 2019 | 8 | 0.270 |
Why?
| | Disease Management | 1 | 2012 | 645 | 0.270 |
Why?
| | Pediatrics | 2 | 2014 | 1114 | 0.270 |
Why?
| | Middle Aged | 25 | 2026 | 35875 | 0.270 |
Why?
| | Peer Review, Research | 1 | 2008 | 36 | 0.260 |
Why?
| | Benzamides | 2 | 2019 | 224 | 0.260 |
Why?
| | Hospitals, Pediatric | 1 | 2011 | 556 | 0.260 |
Why?
| | Mice, Inbred DBA | 5 | 2020 | 187 | 0.260 |
Why?
| | Benzimidazoles | 2 | 2019 | 190 | 0.260 |
Why?
| | Graft vs Host Disease | 2 | 2023 | 264 | 0.260 |
Why?
| | Arthroplasty | 5 | 2017 | 59 | 0.260 |
Why?
| | Collagen Type II | 3 | 2020 | 54 | 0.250 |
Why?
| | Serum Response Factor | 2 | 2019 | 33 | 0.250 |
Why?
| | Macrophages | 4 | 2019 | 1511 | 0.250 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 206 | 0.250 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2017 | 66 | 0.250 |
Why?
| | Program Development | 1 | 2009 | 370 | 0.250 |
Why?
| | Family | 1 | 2011 | 679 | 0.250 |
Why?
| | Postoperative Complications | 3 | 2014 | 2919 | 0.240 |
Why?
| | TWEAK Receptor | 1 | 2026 | 6 | 0.240 |
Why?
| | Drug Design | 2 | 2019 | 173 | 0.240 |
Why?
| | Nipecotic Acids | 2 | 2017 | 6 | 0.230 |
Why?
| | Glycoproteins | 2 | 2001 | 355 | 0.230 |
Why?
| | Adult | 21 | 2026 | 40449 | 0.230 |
Why?
| | Sjogren's Syndrome | 1 | 2025 | 37 | 0.230 |
Why?
| | Hydroxychloroquine | 1 | 2026 | 63 | 0.230 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 985 | 0.230 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 62 | 0.230 |
Why?
| | Citrulline | 3 | 2020 | 46 | 0.230 |
Why?
| | Stromal Cells | 1 | 2025 | 124 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2145 | 0.220 |
Why?
| | Periodicals as Topic | 1 | 2008 | 203 | 0.220 |
Why?
| | Mice, Inbred C57BL | 13 | 2019 | 5992 | 0.220 |
Why?
| | Th2 Cells | 3 | 2013 | 171 | 0.220 |
Why?
| | Abatacept | 3 | 2022 | 56 | 0.220 |
Why?
| | Aged | 17 | 2026 | 25913 | 0.220 |
Why?
| | Glucocorticoids | 2 | 2019 | 535 | 0.220 |
Why?
| | Osteoblasts | 1 | 2005 | 145 | 0.220 |
Why?
| | Antigen Presentation | 2 | 2020 | 205 | 0.220 |
Why?
| | Hyaluronan Receptors | 1 | 2025 | 102 | 0.210 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2024 | 24 | 0.210 |
Why?
| | Rituximab | 1 | 2025 | 209 | 0.210 |
Why?
| | Actomyosin | 1 | 2024 | 19 | 0.210 |
Why?
| | Benzylisoquinolines | 1 | 2023 | 2 | 0.210 |
Why?
| | Antiphospholipid Syndrome | 1 | 2024 | 33 | 0.200 |
Why?
| | Cell Membrane | 1 | 2007 | 706 | 0.200 |
Why?
| | Arthroplasty, Replacement | 2 | 2015 | 47 | 0.200 |
Why?
| | Tacrolimus Binding Protein 1A | 2 | 2022 | 10 | 0.200 |
Why?
| | Lymphoma, T-Cell | 1 | 2023 | 29 | 0.200 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 53 | 0.200 |
Why?
| | Calcineurin Inhibitors | 2 | 2022 | 69 | 0.190 |
Why?
| | Arthroplasty, Replacement, Finger | 2 | 2014 | 3 | 0.190 |
Why?
| | Primary Health Care | 2 | 2019 | 1733 | 0.190 |
Why?
| | Mice, Transgenic | 6 | 2020 | 2182 | 0.190 |
Why?
| | Optic Neuritis | 1 | 2023 | 44 | 0.190 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 851 | 0.190 |
Why?
| | Transcription, Genetic | 4 | 2019 | 1496 | 0.190 |
Why?
| | Retinal Pigments | 1 | 2022 | 6 | 0.190 |
Why?
| | Sulfatases | 1 | 2022 | 5 | 0.190 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2025 | 239 | 0.190 |
Why?
| | Calcineurin | 2 | 2022 | 105 | 0.190 |
Why?
| | Autoimmunity | 2 | 2021 | 926 | 0.190 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 143 | 0.190 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2022 | 48 | 0.190 |
Why?
| | Mice, SCID | 2 | 2021 | 369 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2363 | 0.180 |
Why?
| | Lipid Metabolism | 1 | 2025 | 527 | 0.180 |
Why?
| | Phagocytosis | 2 | 2023 | 299 | 0.180 |
Why?
| | Osteoarthritis | 3 | 2019 | 196 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2015 | 427 | 0.170 |
Why?
| | Transforming Growth Factor beta | 3 | 2024 | 479 | 0.170 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2001 | 16 | 0.170 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2001 | 20 | 0.170 |
Why?
| | Gangliosides | 1 | 2001 | 23 | 0.170 |
Why?
| | Trans-Activators | 3 | 2019 | 405 | 0.170 |
Why?
| | Quantitative Trait Loci | 1 | 2023 | 374 | 0.170 |
Why?
| | Pyrroles | 1 | 2022 | 217 | 0.170 |
Why?
| | Cell Movement | 4 | 2019 | 965 | 0.170 |
Why?
| | Monocytes | 3 | 2019 | 538 | 0.160 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 83 | 0.160 |
Why?
| | Cell Line, Tumor | 4 | 2023 | 3540 | 0.160 |
Why?
| | Hemeproteins | 1 | 2020 | 8 | 0.160 |
Why?
| | Malassezia | 1 | 2020 | 5 | 0.160 |
Why?
| | Prospective Studies | 8 | 2021 | 7990 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2021 | 93 | 0.160 |
Why?
| | Colitis | 1 | 2023 | 280 | 0.160 |
Why?
| | Receptors, Lysosphingolipid | 1 | 2020 | 13 | 0.160 |
Why?
| | Receptors, Cytokine | 1 | 2020 | 36 | 0.160 |
Why?
| | Patient Readmission | 2 | 2016 | 758 | 0.150 |
Why?
| | Crystallography, X-Ray | 5 | 2020 | 492 | 0.150 |
Why?
| | Aspergillus fumigatus | 1 | 2019 | 25 | 0.150 |
Why?
| | Interleukin-10 | 2 | 2013 | 309 | 0.150 |
Why?
| | Disease Models, Animal | 9 | 2022 | 4557 | 0.150 |
Why?
| | Complement C3-C5 Convertases | 1 | 2019 | 22 | 0.150 |
Why?
| | Citrullination | 1 | 2019 | 13 | 0.150 |
Why?
| | Interferons | 1 | 2021 | 188 | 0.150 |
Why?
| | Retina | 2 | 2022 | 324 | 0.150 |
Why?
| | Histones | 2 | 2022 | 669 | 0.150 |
Why?
| | Complement C5 | 1 | 2019 | 33 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 732 | 0.150 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2019 | 26 | 0.150 |
Why?
| | Apoptosis | 4 | 2013 | 2430 | 0.150 |
Why?
| | Oxadiazoles | 1 | 2019 | 37 | 0.150 |
Why?
| | Carboxylic Acids | 1 | 2019 | 34 | 0.150 |
Why?
| | Interleukin-7 | 1 | 2019 | 65 | 0.150 |
Why?
| | Medicare | 2 | 2015 | 886 | 0.140 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 56 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2010 | 668 | 0.140 |
Why?
| | Synovial Fluid | 4 | 2019 | 67 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2016 | 6429 | 0.140 |
Why?
| | Collagen | 2 | 2015 | 456 | 0.140 |
Why?
| | Patient-Centered Care | 2 | 2014 | 544 | 0.140 |
Why?
| | Complement C3 | 1 | 2019 | 191 | 0.140 |
Why?
| | Interleukin-11 | 1 | 2018 | 10 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 3 | 2022 | 969 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2019 | 135 | 0.140 |
Why?
| | Fragile X Syndrome | 1 | 2019 | 118 | 0.140 |
Why?
| | CD3 Complex | 3 | 2024 | 111 | 0.140 |
Why?
| | DNA-Binding Proteins | 2 | 2017 | 1499 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 573 | 0.140 |
Why?
| | Galectins | 1 | 2018 | 27 | 0.130 |
Why?
| | Brain Diseases | 1 | 2019 | 152 | 0.130 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 233 | 0.130 |
Why?
| | Child, Preschool | 5 | 2016 | 11787 | 0.130 |
Why?
| | RNA, Messenger | 7 | 2021 | 2832 | 0.130 |
Why?
| | Joint Capsule | 1 | 2017 | 10 | 0.130 |
Why?
| | Hemolysis | 1 | 2019 | 243 | 0.130 |
Why?
| | Rho Factor | 1 | 2017 | 4 | 0.130 |
Why?
| | Infant | 4 | 2016 | 10034 | 0.130 |
Why?
| | MicroRNAs | 1 | 2024 | 701 | 0.130 |
Why?
| | Chemotactic Factors | 1 | 2017 | 43 | 0.130 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 36 | 0.130 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2018 | 133 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 1999 | 377 | 0.130 |
Why?
| | Joints | 1 | 2018 | 107 | 0.120 |
Why?
| | Antigens, Surface | 2 | 2013 | 157 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2017 | 61 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11679 | 0.120 |
Why?
| | North Carolina | 1 | 2016 | 128 | 0.120 |
Why?
| | Interleukin-2 | 3 | 2007 | 437 | 0.120 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2017 | 56 | 0.120 |
Why?
| | Cartilage, Articular | 1 | 2020 | 343 | 0.120 |
Why?
| | Th1 Cells | 3 | 2020 | 139 | 0.120 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2017 | 132 | 0.120 |
Why?
| | Protein Kinase C | 2 | 1994 | 252 | 0.120 |
Why?
| | Spleen | 2 | 2009 | 508 | 0.120 |
Why?
| | Aptamers, Nucleotide | 1 | 2017 | 85 | 0.120 |
Why?
| | Surveys and Questionnaires | 6 | 2024 | 6048 | 0.120 |
Why?
| | Gene Expression Profiling | 4 | 2026 | 1782 | 0.120 |
Why?
| | Adolescent | 8 | 2020 | 22428 | 0.120 |
Why?
| | Immunophenotyping | 2 | 2011 | 322 | 0.120 |
Why?
| | Memory | 1 | 2018 | 295 | 0.120 |
Why?
| | Mice, Knockout | 6 | 2020 | 3121 | 0.120 |
Why?
| | Child | 6 | 2016 | 22633 | 0.120 |
Why?
| | Postoperative Period | 1 | 2016 | 354 | 0.110 |
Why?
| | Toll-Like Receptors | 1 | 2016 | 194 | 0.110 |
Why?
| | Interleukin-6 | 4 | 2017 | 780 | 0.110 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2015 | 35 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 824 | 0.110 |
Why?
| | Emergency Treatment | 1 | 2016 | 124 | 0.110 |
Why?
| | Laminin | 1 | 2015 | 72 | 0.110 |
Why?
| | Nitric Oxide | 1 | 2020 | 897 | 0.110 |
Why?
| | Hand Joints | 1 | 2015 | 4 | 0.110 |
Why?
| | Histone Deacetylases | 1 | 2016 | 210 | 0.110 |
Why?
| | Oxidative Stress | 3 | 2020 | 1339 | 0.110 |
Why?
| | Disease Progression | 2 | 2013 | 2847 | 0.110 |
Why?
| | Proteoglycans | 1 | 2015 | 110 | 0.110 |
Why?
| | Transcriptional Activation | 1 | 2017 | 383 | 0.110 |
Why?
| | rho-Associated Kinases | 1 | 2015 | 83 | 0.110 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2015 | 51 | 0.110 |
Why?
| | Complement System Proteins | 1 | 2018 | 316 | 0.110 |
Why?
| | Cell Line | 5 | 2017 | 2882 | 0.110 |
Why?
| | Membrane Glycoproteins | 1 | 2017 | 496 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2608 | 0.110 |
Why?
| | Wrist Joint | 1 | 2015 | 71 | 0.110 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 153 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2016 | 341 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1370 | 0.100 |
Why?
| | Cell Proliferation | 6 | 2019 | 2496 | 0.100 |
Why?
| | Biomarkers | 3 | 2026 | 4271 | 0.100 |
Why?
| | Drug Combinations | 1 | 2015 | 390 | 0.100 |
Why?
| | Cell Lineage | 2 | 2010 | 376 | 0.100 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 4 | 0.100 |
Why?
| | Ultrasonography | 1 | 2018 | 770 | 0.100 |
Why?
| | Thioctic Acid | 1 | 2014 | 12 | 0.100 |
Why?
| | Dermis | 1 | 2014 | 32 | 0.100 |
Why?
| | Chemokine CXCL9 | 1 | 2013 | 38 | 0.100 |
Why?
| | Phosphorylation | 2 | 2015 | 1732 | 0.100 |
Why?
| | Voriconazole | 1 | 2013 | 21 | 0.100 |
Why?
| | Upper Extremity | 1 | 2015 | 112 | 0.100 |
Why?
| | Cohort Studies | 6 | 2017 | 5960 | 0.100 |
Why?
| | Quality of Life | 3 | 2018 | 3185 | 0.100 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2013 | 46 | 0.100 |
Why?
| | Range of Motion, Articular | 3 | 2013 | 421 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 889 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2007 | 379 | 0.100 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 478 | 0.100 |
Why?
| | Rats | 4 | 2026 | 5597 | 0.100 |
Why?
| | Interleukin-5 | 1 | 2013 | 39 | 0.100 |
Why?
| | Carrier Proteins | 1 | 1997 | 737 | 0.100 |
Why?
| | Calreticulin | 1 | 2013 | 22 | 0.100 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 145 | 0.100 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 570 | 0.100 |
Why?
| | Patient Care Planning | 1 | 2014 | 169 | 0.100 |
Why?
| | Antibodies, Blocking | 2 | 2007 | 37 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2026 | 2029 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2019 | 2925 | 0.100 |
Why?
| | Congresses as Topic | 1 | 2014 | 221 | 0.100 |
Why?
| | Blotting, Western | 4 | 2016 | 1187 | 0.090 |
Why?
| | Myofibroblasts | 1 | 2014 | 143 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 215 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 240 | 0.090 |
Why?
| | Patient Participation | 2 | 2014 | 431 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2019 | 17066 | 0.090 |
Why?
| | Osteoclasts | 3 | 2019 | 52 | 0.090 |
Why?
| | Cell Death | 2 | 2024 | 383 | 0.090 |
Why?
| | Hip Joint | 1 | 2013 | 172 | 0.090 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 210 | 0.090 |
Why?
| | Infant, Premature | 1 | 2016 | 611 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 14105 | 0.090 |
Why?
| | CD4 Antigens | 2 | 2007 | 139 | 0.090 |
Why?
| | Health Services Research | 1 | 2014 | 396 | 0.090 |
Why?
| | Length of Stay | 2 | 2015 | 1337 | 0.090 |
Why?
| | Hand Strength | 2 | 2011 | 144 | 0.090 |
Why?
| | STAT6 Transcription Factor | 1 | 2011 | 24 | 0.090 |
Why?
| | GATA3 Transcription Factor | 1 | 2011 | 22 | 0.090 |
Why?
| | Lung | 1 | 2025 | 4109 | 0.090 |
Why?
| | Factor Analysis, Statistical | 1 | 2012 | 293 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 846 | 0.090 |
Why?
| | United States | 7 | 2024 | 15966 | 0.090 |
Why?
| | Medicine in the Arts | 1 | 2011 | 2 | 0.080 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 334 | 0.080 |
Why?
| | Outpatients | 1 | 2015 | 442 | 0.080 |
Why?
| | Biological Products | 1 | 2014 | 252 | 0.080 |
Why?
| | Early Diagnosis | 1 | 2012 | 249 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 427 | 0.080 |
Why?
| | Lower Extremity | 1 | 2015 | 438 | 0.080 |
Why?
| | Major Histocompatibility Complex | 2 | 2005 | 229 | 0.080 |
Why?
| | Medicaid | 1 | 2015 | 461 | 0.080 |
Why?
| | Bleomycin | 2 | 2024 | 253 | 0.080 |
Why?
| | National Health Programs | 1 | 2010 | 23 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1356 | 0.080 |
Why?
| | Hospitalists | 1 | 2014 | 266 | 0.080 |
Why?
| | Protein Binding | 2 | 2018 | 2273 | 0.080 |
Why?
| | Cell Separation | 1 | 2011 | 307 | 0.080 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 207 | 0.080 |
Why?
| | Interphase | 2 | 2001 | 38 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2013 | 1173 | 0.080 |
Why?
| | Pinch Strength | 1 | 2009 | 3 | 0.080 |
Why?
| | Binding Sites | 3 | 2019 | 1329 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1489 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2014 | 704 | 0.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2009 | 131 | 0.070 |
Why?
| | Allosteric Regulation | 2 | 2019 | 98 | 0.070 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1253 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2947 | 0.070 |
Why?
| | Receptors, Pattern Recognition | 1 | 2008 | 12 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2015 | 8265 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 2 | 2019 | 91 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 573 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2024 | 893 | 0.070 |
Why?
| | B7 Antigens | 1 | 2008 | 18 | 0.070 |
Why?
| | Lipopolysaccharides | 2 | 2023 | 863 | 0.070 |
Why?
| | CD28 Antigens | 2 | 2022 | 58 | 0.070 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 27 | 0.070 |
Why?
| | Molecular Structure | 2 | 2019 | 499 | 0.070 |
Why?
| | Prognosis | 2 | 2017 | 4282 | 0.070 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2008 | 69 | 0.070 |
Why?
| | Mycoses | 1 | 2008 | 88 | 0.070 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2007 | 138 | 0.060 |
Why?
| | Superantigens | 2 | 1997 | 70 | 0.060 |
Why?
| | Gene Expression | 3 | 2019 | 1490 | 0.060 |
Why?
| | History, 21st Century | 1 | 2008 | 219 | 0.060 |
Why?
| | Enterotoxins | 2 | 1997 | 89 | 0.060 |
Why?
| | Connective Tissue Growth Factor | 2 | 2019 | 27 | 0.060 |
Why?
| | Hybridomas | 1 | 2007 | 234 | 0.060 |
Why?
| | Models, Animal | 2 | 2019 | 392 | 0.060 |
Why?
| | Calcium | 3 | 2022 | 1183 | 0.060 |
Why?
| | History, 20th Century | 1 | 2008 | 325 | 0.060 |
Why?
| | Molecular Dynamics Simulation | 2 | 2019 | 259 | 0.060 |
Why?
| | Colorado | 1 | 2016 | 4564 | 0.060 |
Why?
| | Hand | 2 | 2010 | 161 | 0.060 |
Why?
| | Cytokine TWEAK | 1 | 2026 | 2 | 0.060 |
Why?
| | Fusion Regulatory Protein-1 | 2 | 1997 | 3 | 0.060 |
Why?
| | Cell Adhesion | 1 | 2007 | 455 | 0.060 |
Why?
| | Salivary Glands | 1 | 2025 | 36 | 0.060 |
Why?
| | Genotype | 1 | 2011 | 1833 | 0.060 |
Why?
| | Virus Diseases | 1 | 2008 | 216 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 983 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5408 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2005 | 140 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2007 | 364 | 0.060 |
Why?
| | Pilot Projects | 1 | 2011 | 1886 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2005 | 39 | 0.050 |
Why?
| | Matrix Metalloproteinase 14 | 1 | 2024 | 3 | 0.050 |
Why?
| | Graft Rejection | 1 | 2008 | 540 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1767 | 0.050 |
Why?
| | Down-Regulation | 2 | 2017 | 627 | 0.050 |
Why?
| | beta 2-Glycoprotein I | 1 | 2024 | 5 | 0.050 |
Why?
| | Interleukin-8 | 2 | 2018 | 271 | 0.050 |
Why?
| | X-Ray Microtomography | 2 | 2015 | 107 | 0.050 |
Why?
| | Laboratory Proficiency Testing | 1 | 2024 | 9 | 0.050 |
Why?
| | NFATC Transcription Factors | 2 | 2015 | 93 | 0.050 |
Why?
| | Pathologists | 1 | 2024 | 19 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2026 | 275 | 0.050 |
Why?
| | Administration, Oral | 2 | 2017 | 847 | 0.050 |
Why?
| | Inflammation Mediators | 2 | 2017 | 509 | 0.050 |
Why?
| | Immunoassay | 1 | 2024 | 109 | 0.050 |
Why?
| | Parents | 1 | 2012 | 1403 | 0.050 |
Why?
| | Up-Regulation | 2 | 2016 | 851 | 0.050 |
Why?
| | Plasma Cells | 1 | 2023 | 75 | 0.050 |
Why?
| | Collagen Type I | 2 | 2014 | 147 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 4089 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2017 | 862 | 0.050 |
Why?
| | Pantothenic Acid | 1 | 2022 | 5 | 0.050 |
Why?
| | Enzyme Activation | 2 | 2014 | 766 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 284 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 177 | 0.050 |
Why?
| | Cytoskeleton | 1 | 2024 | 195 | 0.050 |
Why?
| | Receptor, Bradykinin B1 | 1 | 2022 | 2 | 0.050 |
Why?
| | Reference Values | 1 | 2024 | 797 | 0.050 |
Why?
| | Models, Molecular | 2 | 2020 | 1618 | 0.050 |
Why?
| | Bradykinin | 1 | 2022 | 48 | 0.050 |
Why?
| | Protein Kinase C-delta | 1 | 2022 | 46 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2022 | 79 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 710 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 3162 | 0.050 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2022 | 153 | 0.050 |
Why?
| | Health Personnel | 1 | 2009 | 748 | 0.050 |
Why?
| | Tight Junctions | 1 | 2022 | 81 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2022 | 163 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2005 | 502 | 0.040 |
Why?
| | Benzodioxoles | 1 | 2023 | 158 | 0.040 |
Why?
| | Carbohydrate Sequence | 1 | 2001 | 28 | 0.040 |
Why?
| | Glucosylceramides | 1 | 2001 | 7 | 0.040 |
Why?
| | E-Selectin | 1 | 2001 | 61 | 0.040 |
Why?
| | Propanolamines | 1 | 2001 | 40 | 0.040 |
Why?
| | Jurkat Cells | 1 | 2001 | 114 | 0.040 |
Why?
| | Keratinocytes | 1 | 2022 | 248 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 161 | 0.040 |
Why?
| | Piperidines | 1 | 2022 | 217 | 0.040 |
Why?
| | Ergosterol | 1 | 2020 | 1 | 0.040 |
Why?
| | Virulence Factors | 1 | 2022 | 172 | 0.040 |
Why?
| | Gene Transfer, Horizontal | 1 | 2020 | 35 | 0.040 |
Why?
| | Dinoprostone | 1 | 2001 | 178 | 0.040 |
Why?
| | Pyrrolidines | 1 | 2001 | 125 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2023 | 928 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2022 | 635 | 0.040 |
Why?
| | Biopsy | 1 | 2023 | 1075 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2020 | 40 | 0.040 |
Why?
| | Coccidioides | 1 | 2019 | 6 | 0.040 |
Why?
| | Visual Analog Scale | 1 | 2019 | 34 | 0.040 |
Why?
| | Georgia | 1 | 2019 | 83 | 0.040 |
Why?
| | Mice, Inbred A | 1 | 2019 | 48 | 0.040 |
Why?
| | Interleukin-12 | 1 | 2020 | 117 | 0.040 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 2020 | 78 | 0.040 |
Why?
| | Placebos | 1 | 2020 | 192 | 0.040 |
Why?
| | Aspergillosis | 1 | 2019 | 23 | 0.040 |
Why?
| | Fungal Proteins | 1 | 2020 | 145 | 0.040 |
Why?
| | U937 Cells | 1 | 2019 | 27 | 0.040 |
Why?
| | Symbiosis | 1 | 2020 | 81 | 0.040 |
Why?
| | CD2 Antigens | 1 | 1999 | 8 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 61 | 0.040 |
Why?
| | Receptors, Interleukin-7 | 1 | 2019 | 28 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2001 | 245 | 0.040 |
Why?
| | Epigenetic Repression | 1 | 2019 | 4 | 0.040 |
Why?
| | Cryptococcosis | 1 | 2019 | 31 | 0.040 |
Why?
| | Ankle Joint | 1 | 2020 | 122 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2011 | 5868 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2019 | 113 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2019 | 85 | 0.040 |
Why?
| | Patient Discharge | 2 | 2016 | 983 | 0.040 |
Why?
| | fas Receptor | 1 | 1999 | 92 | 0.040 |
Why?
| | Infliximab | 1 | 2019 | 108 | 0.040 |
Why?
| | Administration, Topical | 1 | 1999 | 150 | 0.040 |
Why?
| | Peptides | 1 | 2005 | 995 | 0.040 |
Why?
| | Vital Capacity | 1 | 2019 | 290 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2019 | 56 | 0.040 |
Why?
| | Gene Deletion | 1 | 2020 | 389 | 0.040 |
Why?
| | Drug Discovery | 1 | 2019 | 155 | 0.030 |
Why?
| | Maze Learning | 1 | 2018 | 103 | 0.030 |
Why?
| | Methylation | 1 | 2019 | 242 | 0.030 |
Why?
| | Receptors, Notch | 1 | 2019 | 92 | 0.030 |
Why?
| | Interleukin-11 Receptor alpha Subunit | 1 | 2018 | 4 | 0.030 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 41 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 628 | 0.030 |
Why?
| | Thymus Gland | 1 | 1999 | 311 | 0.030 |
Why?
| | Hemoglobins | 1 | 2020 | 384 | 0.030 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2018 | 30 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2019 | 320 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 1997 | 41 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2018 | 268 | 0.030 |
Why?
| | Nerve Fibers | 1 | 2018 | 104 | 0.030 |
Why?
| | Receptors, Interleukin-2 | 1 | 1997 | 64 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2018 | 198 | 0.030 |
Why?
| | A549 Cells | 1 | 2017 | 75 | 0.030 |
Why?
| | Binding, Competitive | 1 | 1997 | 193 | 0.030 |
Why?
| | Serum Response Element | 1 | 2017 | 6 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.030 |
Why?
| | Zymosan | 1 | 2017 | 39 | 0.030 |
Why?
| | Hyperalgesia | 1 | 2018 | 131 | 0.030 |
Why?
| | Follistatin-Related Proteins | 1 | 2016 | 2 | 0.030 |
Why?
| | Nectins | 1 | 2016 | 7 | 0.030 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2016 | 7 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2022 | 748 | 0.030 |
Why?
| | Paclitaxel | 1 | 2018 | 255 | 0.030 |
Why?
| | Dexamethasone | 1 | 1999 | 372 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1406 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2001 | 2930 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2016 | 93 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 173 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1997 | 175 | 0.030 |
Why?
| | Neuralgia | 1 | 2018 | 144 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2017 | 215 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2020 | 514 | 0.030 |
Why?
| | RNA Interference | 1 | 2018 | 476 | 0.030 |
Why?
| | Clone Cells | 1 | 1996 | 266 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 1997 | 220 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2011 | 1326 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 459 | 0.030 |
Why?
| | Knee Joint | 1 | 2019 | 426 | 0.030 |
Why?
| | Phylogeny | 1 | 2020 | 1016 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 336 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2019 | 519 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1463 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 488 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 370 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 395 | 0.030 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2014 | 20 | 0.030 |
Why?
| | Arthrodesis | 1 | 2015 | 35 | 0.030 |
Why?
| | RANK Ligand | 1 | 2014 | 26 | 0.030 |
Why?
| | Cell Division | 1 | 1996 | 766 | 0.030 |
Why?
| | Cycloheximide | 1 | 1994 | 46 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2003 | 1185 | 0.030 |
Why?
| | Databases, Protein | 1 | 2014 | 90 | 0.030 |
Why?
| | Cell Cycle | 1 | 1997 | 596 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 744 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 442 | 0.030 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 4 | 0.030 |
Why?
| | Spinal Cord | 1 | 2017 | 380 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 14 | 0.030 |
Why?
| | Sulfurtransferases | 1 | 2014 | 9 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 19 | 0.030 |
Why?
| | Lymphoid Tissue | 1 | 2014 | 80 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 22 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2019 | 592 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2027 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1741 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 148 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2014 | 84 | 0.030 |
Why?
| | Lysophospholipids | 1 | 2014 | 77 | 0.020 |
Why?
| | Species Specificity | 1 | 2014 | 574 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 304 | 0.020 |
Why?
| | Databases, Factual | 1 | 2019 | 1486 | 0.020 |
Why?
| | Mycobacterium | 1 | 2014 | 116 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2014 | 98 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 455 | 0.020 |
Why?
| | Immunoblotting | 1 | 2013 | 300 | 0.020 |
Why?
| | Biomimetic Materials | 1 | 2013 | 76 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 405 | 0.020 |
Why?
| | Cartilage | 1 | 2014 | 198 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 89 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1047 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2013 | 109 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 2527 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1166 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 381 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2018 | 846 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1716 | 0.020 |
Why?
| | Reoperation | 1 | 2015 | 630 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2013 | 180 | 0.020 |
Why?
| | Arginine | 1 | 2013 | 262 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 416 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 375 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1539 | 0.020 |
Why?
| | Medicine in Literature | 1 | 2011 | 4 | 0.020 |
Why?
| | History, 17th Century | 1 | 2011 | 14 | 0.020 |
Why?
| | History, 16th Century | 1 | 2011 | 14 | 0.020 |
Why?
| | Paleopathology | 1 | 2011 | 11 | 0.020 |
Why?
| | History, Ancient | 1 | 2011 | 55 | 0.020 |
Why?
| | Linear Models | 1 | 2013 | 854 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 147 | 0.020 |
Why?
| | England | 1 | 2010 | 111 | 0.020 |
Why?
| | Computational Biology | 1 | 2014 | 680 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2014 | 780 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 834 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2011 | 310 | 0.020 |
Why?
| | Models, Statistical | 1 | 2013 | 681 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2014 | 955 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2879 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1813 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7190 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 1053 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2017 | 2452 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2310 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2003 | 539 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10779 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|